LPS-responsive beige-like anchor protein deficiency

Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD's medical weight loss NYC, sleep center NYC
Philadelphia medical weight loss and Philadelphia sleep clinics
| LPS-responsive beige-like anchor protein deficiency | |
|---|---|
| Synonyms | LPS-responsive beige-like anchor protein deficiency syndrome |
| Pronounce | N/A |
| Specialty | N/A |
| Symptoms | Recurrent infections, fever, hepatosplenomegaly, failure to thrive |
| Complications | Sepsis, autoimmune disorders |
| Onset | Infancy |
| Duration | Chronic |
| Types | N/A |
| Causes | Mutations in the LRBA gene |
| Risks | Family history of the condition |
| Diagnosis | Genetic testing, immunological assays |
| Differential diagnosis | Common variable immunodeficiency, X-linked agammaglobulinemia |
| Prevention | N/A |
| Treatment | Immunoglobulin replacement therapy, hematopoietic stem cell transplantation |
| Medication | Corticosteroids, immunosuppressants |
| Prognosis | Variable, depending on treatment and complications |
| Frequency | Rare |
| Deaths | N/A |
LPS-responsive beige-like anchor (LRBA) protein deficiency is a rare immunodeficiency disorder characterized by a mutation in the LRBA gene. This condition affects the immune system, leading to a wide range of clinical manifestations including autoimmunity, recurrent infections, and enteropathy. LRBA protein plays a crucial role in the regulation of immune cell function, particularly in the maintenance and survival of regulatory T cells (Tregs) and the trafficking of intracellular vesicles.
Etiology[edit]
LRBA deficiency is caused by autosomal recessive mutations in the LRBA gene located on chromosome 4q31. This gene encodes the LRBA protein, which is involved in the intracellular trafficking processes that are essential for the normal function of the immune system. The mutations lead to either a significant reduction or a complete loss of LRBA protein function.
Clinical Manifestations[edit]
Patients with LRBA deficiency present a broad spectrum of clinical features, which can vary significantly among affected individuals. Common symptoms include:
- Autoimmune diseases such as autoimmune hemolytic anemia, autoimmune thrombocytopenia, and autoimmune enteropathy.
- Recurrent infections due to the impaired immune response.
- Enteropathy characterized by diarrhea, which can lead to failure to thrive in children.
- Endocrinopathy, often presenting as hypothyroidism.
- Lung disease, including interstitial lung disease and bronchiectasis.
Diagnosis[edit]
The diagnosis of LRBA deficiency is based on clinical presentation, laboratory findings, and genetic testing. Laboratory tests may reveal abnormalities such as low immunoglobulin levels, elevated autoantibodies, and reduced numbers of regulatory T cells. Confirmatory diagnosis is achieved through genetic testing, which identifies mutations in the LRBA gene.
Treatment[edit]
Treatment of LRBA deficiency is tailored to the individual's symptoms and may include:
- Immunoglobulin therapy to prevent infections.
- Immunosuppressive therapy to control autoimmune manifestations. Medications such as rituximab, sirolimus, or abatacept may be used.
- Hematopoietic stem cell transplantation (HSCT) has been successful in some cases, offering the potential for a cure by reconstituting a functional immune system.
Prognosis[edit]
The prognosis for individuals with LRBA deficiency varies depending on the severity of symptoms and the effectiveness of treatment. Early diagnosis and appropriate management are crucial for improving outcomes. However, the condition can be life-threatening, particularly in cases with severe autoimmune complications or infections.
See Also[edit]
- Primary immunodeficiency
- Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED)
- Common variable immunodeficiency (CVID)
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
